AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NovoCure Ltd Director's Dealing 2024

Feb 29, 2024

31949_dirs_2024-02-29_804ff368-1dd3-40ed-b1e7-c25c55090356.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2024-02-27

Reporting Person: Cordova Ashley (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-02-27	Ordinary Shares	A	102249.00	$16.30	Acquired	219867.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-02-27	Stock Options (Right to buy)	$16.30	A	156348.00	Acquired	2034-02-26	Ordinary Shares (156348.00)	Direct

Footnotes

F1: Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.

F2: Options to buy 156,348 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.